You don't have javascript enabled. Good luck with that.
Skip to content
FOR US HEALTHCARE PROFESSIONALS

Strongly recommended by AAD and AAAAI guidelines as a systemic therapy for moderate-to-severe atopic dermatitis in adult patients1,2

PEDIATRIC (AGES 12-17)

Efficacy Results


Significant improvements in skin clearance
and lesion extent and severity3,4

EASI-75

Pediatric patients achieving EASI-75 at Week 164*†

At Week 16, more than 4x as many patients treated with Adbry 150 mg q2w monotherapy achieved the primary endpoint of EASI-75 compared with placebo3

In ECZTRA 6, a higher proportion of subjects in the Adbry 150 mg every other week group achieved EASI-90 compared with placebo3

*Full Analysis Set (FAS) includes all subjects randomized and dosed.
†Subjects who received rescue treatment from Week 2 to Week 16 or had missing data were considered nonresponders.

EASI-75=improvement of at least 75% in Eczema Area and Severity Index; EASI-90=improvement of at least 90% in EASI; q2w=every 2 weeks.

IGA 0/1

Pediatric patients achieving IGA 0/1 at Week 164*†

At Week 16, more than 5x as many patients treated with Adbry 150 mg q2w monotherapy achieved the primary endpoint of IGA 0/1 compared with placebo3

*Full Analysis Set (FAS) includes all subjects randomized and dosed.
†Subjects who received rescue treatment from Week 2 to Week 16 or had missing data were considered nonresponders.

IGA 0/1=Score of 0/1 using the Investigator’s Global Assessment scale; q2w=every 2 weeks.

Itch NRS

Patients experienced significant
itch relief at Week 163,4

Percentage of patients achieving a ≥4-point
improvement in Adolescent Worst Pruritus NRS
at Week 164*†‡

At Week 16, more than 7x as many patients treated with Adbry 150 mg q2w monotherapy experienced reduction of ≥4 points in Adolescent Worst Pruritus NRS compared with placebo3

*Full Analysis Set (FAS) includes all subjects randomized and dosed.
†Subjects who received rescue treatment from Week 2 to Week 16 or had missing data were considered nonresponders.
‡Subjects with baseline Adolescent Worst Pruritus NRS (weekly average) ≥4.

NRS=Numeric Rating Scale; q2w=every 2 weeks.